BI-69A11

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: BI-69A11
• 英文别名: (E)-3-(3-(1H-benzo[d]imidazol-2-yl)acryloyl)-6-chloro-4-phenylquinolin-2(1H)-one；(E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one；3-[(E)-3-(1H-benzimidazol-2-yl)prop-2-enoyl]-6-chloro-4-phenyl-1H-quinolin-2-one
• 化学式: C₂₅H₁₆ClN₃O₂
• 分子量: 425.874
• InChiKey: SBOKKVUBLNZTCT-OUKQBFOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  BI-69A11 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 12.0h， 以75%的产率得到3-(3-(1H-benzo[d]imidazol-2-yl)propanoyl)-6-chloro-4-phenylquinolin-2(1H)-one
  参考文献：
  名称：

  Synthesis and SAR Studies of Dual AKT/NF-κB Inhibitors Against Melanoma

  摘要：

  The protein Kinase B alpha (AKT) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up‐regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI‐69A11) as inhibitor of the AKT and the NF‐κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model.

  DOI：

  10.1111/cbdd.12177
• 作为产物：
  描述：

  2-氨基-5-氯二苯甲酮 在 cerium(III) chloride heptahydrate 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 16.38h， 生成 BI-69A11
  参考文献：
  名称：

  Synthesis and SAR Studies of Dual AKT/NF-κB Inhibitors Against Melanoma

  摘要：

  The protein Kinase B alpha (AKT) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up‐regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI‐69A11) as inhibitor of the AKT and the NF‐κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model.

  DOI：

  10.1111/cbdd.12177

文献信息

• Quinolinones as Inhibitors of Translation Initiation Complex
  申请人：Sanford-Burnham Medical Research Institute

  公开号：US20180044324A1

  公开（公告）日：2018-02-15

  Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

  本文提供了含喹啉酮的化合物和药物组合物。这些喹啉酮及其组合物可用作真核翻译起始因子4F（eIF4F）复合物调节剂。
• Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20050165053A1

  公开（公告）日：2005-07-28

  The present invention is directed to substituted 4-Aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs thereof, represented by the general Formula I: wherein Ar 1 , Ar 2 , R 1 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及替代的4-芳基-3-(3-芳基-1-氧代-2-丙烯基)-2(1H)-喹啉酮及其类似物，由通式I所表示，其中Ar1，Ar2，R1-R6和R12在此被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于在许多临床情况下诱导细胞死亡，其中存在异常细胞的不受控制的生长和扩散。
• Quinolinones as inhibitors of translation initiation complex
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10577349B2

  公开（公告）日：2020-03-03

  Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

  本文提供了包含喹啉酮的化合物和药物组合物。这些喹啉酮类化合物及其组合物可用作真核生物翻译起始因子 4F（eIF4F）复合物调节剂。
• SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME
  申请人：Sanford-Burnham Medical Research Institute

  公开号：EP2381779A1

  公开（公告）日：2011-11-02
• SCREENING METHODS FOR PROTEIN KINASE B INHIBITORS EMPLOYING VIRTUAL DOCKING APPROACHES AND COMPOUNDS AND COMPOSITIONS DISCOVERED THEREBY
  申请人：Forino Martino

  公开号：US20090131474A1

  公开（公告）日：2009-05-21

  The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase, also known as Protein Kinase B, an enzyme that is believed to play a key role in the inhibition of apoptosis and thus in the etiology of cancer and other conditions, including neurodegenerative diseases. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the compounds with a target binding site derived from the crystal structure of a ternary complex involving Akt1, a nonhydrolyzable ATP analogue, and a peptide substrate derived from a physiological AKT substrate such that the protein active site is defined including those residues within a defined distance from the nonhydrolyzable ATP analogue; (3) ranking the docked compounds by goodness of fit; (4) further selecting compounds from compounds high ranked by goodness of fit in docking by using one or more screening criteria; (5) optionally, visually analyzing structures of compounds selected in step (4) to remove any compounds with improbable docking geometry; and (6) experimentally testing the selected compounds from step (4) or step (5), if step (5) is performed, to determine their inhibitory activity against Akt1 in order to select compounds with Akt1 inhibitory activity. The invention also encompasses pharmaceutical compositions including compounds whose inhibitory activity against Akt1 is discovered by the screening method, as well as methods of use of the pharmaceutical compositions to treat cancer and other conditions.